RAAPID vs Xsolis (2026)
Two vendors applying models where clinical documentation turns into money, and both publish structural answers a buyer can check. RAAPID links every suggested condition code back to specific clinical evidence, which makes explainability a property of the architecture rather than a claim, with coder validation built into the workflow. Xsolis scores medical necessity continuously and sits between payer and provider so both argue from the same number, with peer reviewed research behind that score. Neither is doing anything improper and both are better documented than their peers. What neither publishes is the calibration figure for its own side, the codes removed against codes added for one, and the appeal overturn rate for the other, and those two numbers are what separate a defensible system from a productive one.
- The explainability architecture is structural: every suggested condition code links back to specific clinical evidence, with coder validation inside the workflow.
- Its security page names HITRUST r2 and SOC 2 Type 2, and it can run inside a customer's own Azure tenant.
- For an organization that must defend added conditions in an audit, evidence linkage is a better answer than an accuracy claim.
- It sits between payer and provider rather than serving one side, scoring medical necessity continuously so both parties argue from the same number.
- Peer reviewed research on its score is published from studies across several United States health systems.
- It states HITRUST risk based certification at the two year tier.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. RAAPID and Xsolis are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | RAAPID | Xsolis |
|---|---|---|
| Primary category | Value Based Care Intelligence | RCM & Prior Auth AI |
| Founded | 2022 | 2013 |
| Headquarters | Louisville, Kentucky, United States | Franklin, Tennessee |
| Website | raapidinc.com | xsolis.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Xsolis
-
Product / capability
Xsolis launched GenAI Peer-to-Peer Clinical Synopsis as an add on inside Dragonfly Advise.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
RAAPID is a Louisville, Kentucky risk adjustment company whose platform is built on what it calls neuro symbolic AI: machine learning combined with a clinical knowledge graph that links every suggested hierarchical condition category code to MEAT based chart evidence, and flags codes the record does not support as well as missed ones.
Source: AI Health Index, September 2026
Xsolis sells AI utilization management to hospitals and health plans. Its Dragonfly platform scores each admitted patient's likelihood of needing inpatient care or observation, using machine learning over the hospital record, so the hospital and the payer can work from the same clinical evidence when they decide status and concurrent authorization.
Source: AI Health Index, September 2026
Questions buyers ask
How do RAAPID and Xsolis work with the EHR?
For RAAPID, the home page describes the prospective solution as EHR integrated and lists API integration and custom workflows for AI as a service; the company's marketplace announcement describes an EHR integrated solution on Azure, and the AI as a service page says the APIs integrate with existing health IT systems.
With Xsolis, the shared clinical access between a health system and its payers through Dragonfly is a distinct integration pattern, since both parties read the same record view. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 22, 2026. No vendor pays for placement.
How are RAAPID and Xsolis priced and sold?
In RAAPID's case, the company sells four solutions (retrospective and prospective risk adjustment, RADV audit, and AI as a service by API) in three service models: a fully managed program in which its certified coders do the work, the platform used by the customer's own coders, or the AI connected to existing systems.
For Xsolis, the offering is a hybrid: alongside the platform the company sells Physician Advisor Services covering night and weekend gaps or operating fully outsourced, so the buy can be software, staffed service, or both. A clinical staffing component behaves very differently from a license. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 22, 2026. No vendor pays for placement.
How do RAAPID and Xsolis handle patient data?
With RAAPID, the platform processes complete clinical documentation for health plans and providers, and the company reports more than 8 million patient records a year. Deployment inside the customer's own Azure tenant keeps charts behind a perimeter the plan controls, which the company describes as PHI never leaving the organization; the hosted and managed options put the documentation in the company's hands.
Xsolis announced HITRUST r2 certification for the platform in March 2022 and described it as a proactive approach to protecting health information; the website privacy policy covers site visitors only. Nothing published states how long clinical data drawn from hospital records is kept, whether it is de identified, or whether it trains the Care Level Score. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 22, 2026. No vendor pays for placement.
What evidence is published for RAAPID and Xsolis?
For RAAPID, the company also asserts industry accuracy of 20 to 30 percent as its comparison baseline, a striking claim about rivals that no cited source supports. Backing from a major corporate venture arm is a signal, but a limited one.
With Xsolis, the Care Level Score predicted inpatient discharge status with an area under the curve of 0.89, and a score of 76 or higher classified status correctly 86 percent of the time. Combining the score with a commercial screening tool did worse than the score alone. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 22, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both apply models to decisions with money attached and neither publishes its calibration: for risk adjustment that is the ratio of codes removed to codes added, and for medical necessity it is the proportion of AI informed adverse determinations overturned on appeal. RAAPID's evidence is specific and quantified but entirely vendor reported with no independent validation located. Neither publishes a bias evaluation or subgroup analysis, and in utilization management an output can end in care being denied.